ClinicalTrials.gg
CompletedNCT04594369ASPENUpdated Dec 16, 2025Results posted

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

A Phase 3 interventional study of Brensocatib 10 mg and Brensocatib 25 mg in Non-Cystic Fibrosis Bronchiectasis, sponsored by Insmed Incorporated. Completed at 373 sites in 36 countries. Open to participants aged 12 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Insmed Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,767
Allocation
Randomized
Ages
12 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Enrollment
Largest of 52
1,767 · median 78
Started
2020
with 3 others
Phase 3
14 of 65
2 open now
Registered
35th of 65
by date
Lead sponsor
3 of 65
Insmed Incorporated

Among the 65 studies in Bronchiectasis with a site in United States, this one has the largest enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2020, is one of 14 in phase 3, and was the 35th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 12 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.

03

Conditions studied

  • Non-Cystic Fibrosis Bronchiectasis

Browse trials for

Keywords

  • ASPEN
  • Brensocatib
  • INS1007
04

Who can participate

Ages eligible
12 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide their signed study to participate.

    a. Adolescent participants must have signed study assent form to participate, and the adolescent's parent or legal guardian must have provided signed informed consent for the adolescent to participate.

  2. Clinical history consistent with non-cystic fibrosis bronchiectasis (NCFBE) (cough, chronic sputum production and/or recurrent respiratory infections) that is confirmed by chest computerized tomography (CT) scan.
  3. At least 2 PEs defined by need for antibiotic prescription by a physician for the signs and symptoms of respiratory infections in the past 12 months before the Screening Visit.

    a. Adolescent participants are required to have at least 1 pulmonary exacerbation in the prior 12 months.

  4. Women must be (defined as no menses for 12 months without an alternative medical cause), surgically sterile, or using highly effective (ie, methods that can achieve a failure rate \<1% per year when used consistently and correctly) from Day 1 to at least 90 days after the last dose.
  5. Male participants with female partners of must be using effective contraception from Day 1 to at least 90 days after the last dose.
  6. Male participants with pregnant or non-pregnant women of child-bearing potential partners must use condoms to avoid potential exposure to the embryo/fetus.

Exclusion criteria

Exclusion Criteria:

  1. A primary diagnosis of (COPD) or asthma as judged by the Investigator.
  2. Bronchiectasis due to cystic fibrosis.
  3. Current smokers as defined per Centers for Disease Control (CDC).
  4. Known or suspected immunodeficiency disorder, including history of invasive opportunistic infections.
  5. Known history of (HIV) infection.
  6. Currently being treated for nontuberculous mycobacteria (NTM) lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis (TB).
  7. Active and current symptomatic infection by 2019 corona virus disease (COVID-19).
  8. Inability to follow the procedures of the study (eg, due to language problems or psychological disorders).
  9. Receiving medications or therapy that are prohibited as concomitant medications.
  10. Previously participated in a clinical trial for brensocatib.
  11. Received any within 4 weeks prior to the first administration of brensocatib.
  12. Suffering an exacerbation 4 weeks before Screening or during the Screening period.
  13. Adult participants only: Have compliance issues with completion of electronic diary entries during the Screening Period and in the opinion of the Investigator, compliance is unlikely to improve during the study.
  14. Participated in any other interventional clinical studies within 3 months before Screening Visit.
  15. History of alcohol or drug abuse within 6 months prior to the Screening Visit.
  16. Is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study.
  17. Known history of to brensocatib or any of its .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,767 participants (actual)

Study arms

  • Experimental
    Brensocatib 10 milligrams (mg)

    Participants will receive brensocatib 10 mg, tablets orally, once daily, for 52 weeks.

    Drug: Brensocatib 10 mg

  • Experimental
    Brensocatib 25 mg

    Participants will receive brensocatib 25 mg, tablets orally, once daily, for 52 weeks.

    Drug: Brensocatib 25 mg

  • Placebo comparator
    Placebo

    Participants will receive a brensocatib-matching placebo, tablets orally, once daily, for 52 weeks.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Annualized Rate of Pulmonary Exacerbations (PEs)

    PE was defined as having 3 or more of these symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe pulmonary exacerbation was that required intravenous (IV) antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.

    Time frame: Up to Week 52

Secondary outcomes

  1. Time to First PE

    PE was defined as having 3 or more of following symptoms for at least 48 hours resulting in physician's decision to prescribe antibiotics:1.Increased cough2.Increased sputum volume or change in sputum consistency3.Increased sputum purulence4.Increased breathlessness \&/or decreased exercise tolerance5.Fatigue \&/or malaise6.Hemoptysis.Severe PE were those requiring IV antibacterial drug treatment \&/or hospitalization. Minimum of 14 days must have occurred between one exacerbation onset and next. Any exacerbation that occurred within 14 days of prior exacerbation was not considered a new exacerbation. Time to first PE was calculated from randomization date to onset date of the first exacerbation. Participants who did not have exacerbation at end of 52-week treatment period were considered as censored at date of Week 52 in Cox proportional hazard model. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil protocol definition.

    Time frame: Up to Week 52

  2. Responder Status for Exacerbation-Free Over the 52-Week Treatment Period

    Responder status was based on percentage of participants who were exacerbation free over 52-weeks of treatment period. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee of pulmonary physicians adjudicated reported PE events to see if they fulfill protocol definition. For discontinuation prior to Week 52 without having experienced a confirmed PE, responder status was imputed by multiple imputation.

    Time frame: Up to Week 52

  3. Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after first second after taking a forced expiration as measured by spirometer. Postbronchodilator FEV1 tests included spirometry tests performed referred to the spirometry performed within 30 minutes after administration of bronchodilator (4 puffs of salbutamol/albuterol, terbutaline or ipratropium). A positive change from baseline indicates an improvement in lung function. Baseline was the most recent non-missing assessment determined as best effort prior to the first dose of the investigational product.

    Time frame: Baseline, Week 52

  4. Annualized Rate of Severe PEs

    Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe PE was defined as those requiring IV antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjucated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.

    Time frame: Up to Week 52

  5. Change From Baseline at Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants

    The QOL-B is a validated, self-administered patient-reported outcome (PRO) that assesses symptoms, functioning, and health-related quality of life for participants with non-cystic fibrosis bronchiectasis (NCFBE). It contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported. Baseline refers to most recent assessment on or before study Day 1.

    Time frame: Baseline, Week 52

  6. Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are AEs that occurred on or after the date of first dose of study drugs and within 28 days after the end of treatment.

    Time frame: Up to Week 56

  7. Plasma Concentration of Brensocatib in Adults (Main Study)

    Time frame: 2 hours (h) post-dose on Day 1; Pre-dose and 2 h post-dose at Weeks 4, 28 and 40; Pre-dose at Weeks 16 and 52

  8. Plasma Concentration of Brensocatib in Adults (PK Substudy)

    Time frame: 0.5 h, 2 h, and 4 to 8 h post-dose on Day 1and at Week 28; Pre-dose and 2 h post-dose at Weeks 4 and 48; Pre-dose at Weeks 16 and 52

  9. Plasma Concentration of Brensocatib in Adolescents (Main Study)

    Time frame: 0.5 h, 2 h, and 4 to 8 h post-dose on Day 1 and at Week 28; Pre-dose and 2 h post-dose at Weeks 4 and 48; Pre-dose at Weeks 16 and 52

07

Results

Posted Dec 16, 2025

Participant flow

Participants took part in the study at 373 sites in 36 countries from 01 Dec 2020 to 28 Oct 2024.

Participant flow — Overall Study
MilestoneBrensocatib 10 Milligrams (mg)Brensocatib 25 mgPlacebo
Started583575563
Completed458466457
Not completed125109106
Withdrew: Adverse event10109
Withdrew: Death248
Withdrew: Lost to follow-up1024
Withdrew: Physician decision223
Withdrew: Protocol deviation132
Withdrew: Withdrawal by subject403237
Withdrew: Reason not specified605643

Outcome measures

PrimaryAnnualized Rate of Pulmonary Exacerbations (PEs)

PE was defined as having 3 or more of these symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe pulmonary exacerbation was that required intravenous (IV) antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.

Time frame:
Up to Week 52
Reported as:
Number · exacerbation per participant-year
Annualized Rate of Pulmonary Exacerbations (PEs)
exacerbation per participant-yearBrensocatib 10 mgBrensocatib 25 mgPlacebo
Annualized Rate of Pulmonary Exacerbations (PEs)1.015 (0.910 to 1.132)1.036 (0.927 to 1.157)1.286 (1.158 to 1.428)
Statistical analysis
  • Brensocatib 10 mg vs Placebo · Negative binomial regression · p = =0.0019 (Adjusted p-value = 0.0038. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value for the primary endpoint was tested at two-sided alpha = 0.01.) · Rate ratio: 0.789 · 95% CI 0.680 to 0.916
  • Brensocatib 25 mg vs Placebo · Negative binomial regression · p = =0.0046 (Adjusted p-value = 0.0048. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value for the primary endpoint was tested at two-sided alpha = 0.01.) · Rate ratio: 0.806 · 95% CI 0.694 to 0.936
SecondaryTime to First PE

PE was defined as having 3 or more of following symptoms for at least 48 hours resulting in physician's decision to prescribe antibiotics:1.Increased cough2.Increased sputum volume or change in sputum consistency3.Increased sputum purulence4.Increased breathlessness \&/or decreased exercise tolerance5.Fatigue \&/or malaise6.Hemoptysis.Severe PE were those requiring IV antibacterial drug treatment \&/or hospitalization. Minimum of 14 days must have occurred between one exacerbation onset and next. Any exacerbation that occurred within 14 days of prior exacerbation was not considered a new exacerbation. Time to first PE was calculated from randomization date to onset date of the first exacerbation. Participants who did not have exacerbation at end of 52-week treatment period were considered as censored at date of Week 52 in Cox proportional hazard model. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil protocol definition.

Time frame:
Up to Week 52
Reported as:
Median · weeks
Time to First PE
weeksBrensocatib 10 mgBrensocatib 25 mgPlacebo
Time to First PE49.000 (40.000 to NA)50.714 (37.571 to NA)36.714 (31.143 to 41.429)
Statistical analysis
  • Brensocatib 10 mg vs Placebo · Cox proportional hazard · p = =0.01 (Adjusted p-value = 0.0200. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value for the secondary endpoints were tested at two-sided alpha = 0.05.) · Hazard ratio (hr): 0.813 · 95% CI 0.695 to 0.952
  • Brensocatib 25 mg vs Placebo · Cox proportional hazard · p = =0.0182 (Adjusted p-value = 0.0364. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value for the secondary endpoints were tested at two-sided alpha = 0.05.) · Hazard ratio (hr): 0.825 · 95% CI 0.703 to 0.968
SecondaryResponder Status for Exacerbation-Free Over the 52-Week Treatment Period

Responder status was based on percentage of participants who were exacerbation free over 52-weeks of treatment period. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee of pulmonary physicians adjudicated reported PE events to see if they fulfill protocol definition. For discontinuation prior to Week 52 without having experienced a confirmed PE, responder status was imputed by multiple imputation.

Time frame:
Up to Week 52
Reported as:
Number · percentage of participants
Responder Status for Exacerbation-Free Over the 52-Week Treatment Period
percentage of participantsBrensocatib 10 mgBrensocatib 25 mgPlacebo
Responder Status for Exacerbation-Free Over the 52-Week Treatment Period48.548.540.3
Statistical analysis
  • Brensocatib 10 mg vs Placebo · Logistic Regression · p = =0.0059 (Adjusted p-value = 0.0200. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value for the secondary endpoints were tested at two-sided alpha = 0.05.) · Odds ratio (or): 1.412 · 95% CI 1.105 to 1.806
  • Brensocatib 25 mg vs Placebo · Logistic Regression · p = =0.0074 (Adjusted p-value = 0.0364. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value for the secondary endpoints were tested at two-sided alpha = 0.05.) · Odds ratio (or): 1.4 · 95% CI 1.095 to 1.792
SecondaryChange From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)

FEV1 was used to assess lung function and is the maximum amount of air that can be forced out in one second after first second after taking a forced expiration as measured by spirometer. Postbronchodilator FEV1 tests included spirometry tests performed referred to the spirometry performed within 30 minutes after administration of bronchodilator (4 puffs of salbutamol/albuterol, terbutaline or ipratropium). A positive change from baseline indicates an improvement in lung function. Baseline was the most recent non-missing assessment determined as best effort prior to the first dose of the investigational product.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · liter (L)
Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)
liter (L)Brensocatib 10 mgBrensocatib 25 mgPlacebo
Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)-0.050 ± 0.0093-0.024 ± 0.0099-0.062 ± 0.0094
Statistical analysis
  • Brensocatib 10 mg vs Placebo · Linear repeated measures model · p = =0.3841 (Adjusted p-value = 0.3841. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value was tested at two-sided alpha = 0.05.) · Difference in least square (ls) mean: 0.011 · 95% CI -0.014 to 0.037
  • Brensocatib 25 mg vs Placebo · Linear repeated measures model · p = =0.0054 (Adjusted p-value = 0.0364. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value was tested at two-sided alpha = 0.05.) · Difference in ls mean: 0.038 · 95% CI 0.011 to 0.065
SecondaryAnnualized Rate of Severe PEs

Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe PE was defined as those requiring IV antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjucated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.

Time frame:
Up to Week 52
Reported as:
Number · exacerbation per participant-year
Annualized Rate of Severe PEs
exacerbation per participant-yearBrensocatib 10 mgBrensocatib 25 mgPlacebo
Annualized Rate of Severe PEs0.137 (0.103 to 0.182)0.137 (0.105 to 0.179)0.185 (0.142 to 0.242)
Statistical analysis
  • Brensocatib 10 mg vs Placebo · Negative binomial regression · p = =0.1277 (Adjusted p-value = 0.3841. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value was tested at two-sided alpha = 0.05.) · Rate ratio: 0.742 · 95% CI 0.505 to 1.089
  • Brensocatib 25 mg vs Placebo · Negative binomial regression · p = =0.1025 (Adjusted p-value = 0.2050. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value was tested at two-sided alpha = 0.05.) · Rate ratio: 0.74 · 95% CI 0.515 to 1.062
SecondaryChange From Baseline at Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants

The QOL-B is a validated, self-administered patient-reported outcome (PRO) that assesses symptoms, functioning, and health-related quality of life for participants with non-cystic fibrosis bronchiectasis (NCFBE). It contains 37 items in 8 domains (Respiratory Symptoms, Physical Functioning, Role Functioning, Emotional Functioning, Social Functioning, Vitality, Health Perceptions and Treatment Burden). Each of the 37 items is scored from 1 to 4, and each of the 8 domains scale scores is standardized on a 0-100 point scale, with higher scores representing fewer symptoms or better functioning. A positive change from Baseline indicates improvement in symptoms. For this outcome measure, change in the respiratory symptoms domain score from Baseline was reported. Baseline refers to most recent assessment on or before study Day 1.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on scale
Change From Baseline at Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants
score on scaleBrensocatib 10 mgBrensocatib 25 mgPlacebo
Change From Baseline at Week 52 in Quality of Life Questionnaire - Bronchiectasis (QOL-B) Respiratory Symptoms Domain Score in Adult Participants6.841 ± 0.77068.575 ± 0.75564.809 ± 0.7500
Statistical analysis
  • Brensocatib 10 mg vs Placebo · linear repeated measures model · p = =0.0594 (Adjusted p-value = 0.3841. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value was tested at two-sided alpha = 0.05.) · Ls mean difference: 2.031 · 95% CI -0.081 to 4.143
  • Brensocatib 25 mg vs Placebo · linear repeated measures model · p = =0.0004 (Adjusted p-value = 0.2050. The enhanced mixture-based gatekeeping procedure was used to control the overall type I error rate. Multiplicity adjusted p-value was tested at two-sided alpha = 0.05.) · Ls mean difference: 3.766 · 95% CI 1.680 to 5.852
SecondaryNumber of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs are AEs that occurred on or after the date of first dose of study drugs and within 28 days after the end of treatment.

Time frame:
Up to Week 56
Reported as:
Count of participants · Participants
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)
ParticipantsBrensocatib 10 mgBrensocatib 25 mgPlacebo
Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)452440448
SecondaryPlasma Concentration of Brensocatib in Adults (Main Study)
Time frame:
2 hours (h) post-dose on Day 1; Pre-dose and 2 h post-dose at Weeks 4, 28 and 40; Pre-dose at Weeks 16 and 52
Reported as:
Geometric mean · nanograms per milliliter (ng/ml)
Plasma Concentration of Brensocatib in Adults (Main Study)
nanograms per milliliter (ng/ml)Brensocatib 10 mgBrensocatib 25 mg
Day 1: 2 h post-dose40.52 ± 69.1134.9 ± 51.4
Week 4: Pre-dose52.60 ± 68.7157.4 ± 70.8
Week 4: 2 h post-dose100.5 ± 32.8293.6 ± 35.1
Week 16: Pre-dose45.19 ± 55.0131.6 ± 69.0
Pre-dose at Week 2849.30 ± 63.9143.0 ± 64.6
Week 28: 2 h post-dose91.79 ± 45.3323.7 ± 40.1
Week 40: Pre-dose45.71 ± 54.2136.8 ± 63.4
Week 40: 2 h post-dose107.3 ± 45.0302.6 ± 40.7
Week 52: Pre-dose45.78 ± 61.7135.4 ± 60.3
SecondaryPlasma Concentration of Brensocatib in Adults (PK Substudy)
Time frame:
0.5 h, 2 h, and 4 to 8 h post-dose on Day 1and at Week 28; Pre-dose and 2 h post-dose at Weeks 4 and 48; Pre-dose at Weeks 16 and 52
Reported as:
Geometric mean · ng/ml
Plasma Concentration of Brensocatib in Adults (PK Substudy)
ng/mlBrensocatib 10 mgBrensocatib 25 mg
Day 1: 0.5 h post-dose34.51 ± 97.985.13 ± 103.5
Day 1: 2 h post-dose44.52 ± 55.0120.0 ± 56.2
Day 1: 4-8 h post-dose38.13 ± 52.9108.5 ± 46.9
Week 4: Pre-dose57.53 ± 53.4131.3 ± 60.2
Week 4: 2 h post-dose100.3 ± 44.1286.7 ± 38.4
Week 16: Pre-dose50.24 ± 58.1138.0 ± 64.5
Week 28: Pre-dose50.33 ± 54.7124.6 ± 59.8
Week 28: 0.5 h post-dose89.75 ± 46.0235.5 ± 53.3
Week 28: 2 h post-dose95.33 ± 35.3271.9 ± 46.0
Week 28: 4-8 h post-dose86.27 ± 40.7246.4 ± 43.7
Week 40: Pre-dose51.80 ± 54.4119.3 ± 51.3
Week 40: 2 h post-dose93.74 ± 32.1271.2 ± 45.0
Week 52: Pre-dose49.93 ± 72.2131.6 ± 56.5
SecondaryPlasma Concentration of Brensocatib in Adolescents (Main Study)
Time frame:
0.5 h, 2 h, and 4 to 8 h post-dose on Day 1 and at Week 28; Pre-dose and 2 h post-dose at Weeks 4 and 48; Pre-dose at Weeks 16 and 52
Reported as:
Geometric mean · ng/ml
Plasma Concentration of Brensocatib in Adolescents (Main Study)
ng/mlBrensocatib 10 mgBrensocatib 25 mg
Day 1: 0.5 h post-dose63.20 ± 51.7109.3 ± 139.1
Day 1: 2 h post-dose68.33 ± 32.5202.5 ± 50.7
Day 1: 4-8 h post-dose56.07 ± 24.1196.1 ± 52.4
Week 4: Pre-dose44.10 ± 64.2126.6 ± 90.4
Week 4: 2 h post-dose134.9 ± 52.8432.9 ± 44.3
Week 16: Pre-dose40.62 ± 51.6158.1 ± 95.7
Week 28: Pre-dose43.74 ± 57.2132.9 ± 96.3
Week 28: 0.5 h post-dose123.4 ± 49.1321.6 ± 93.8
Week 28: 2 h post-dose118.5 ± 30.5336.9 ± 77.7
Week 28: 4-8 h post-dose115.4 ± 27.7309.9 ± 48.0
Week 40: Pre-dose37.30 ± 52.584.39 ± 102.3
Week 40: 2 h post-dose110.4 ± 43.9262.8 ± 77.6
Week 52: Pre-dose43.02 ± 64.8104.0 ± 57.8

Adverse events

Collected over Up to Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brensocatib 10 mg2/582 (0.3%)101/582 (17.4%)197/582 (33.8%)
Brensocatib 25 mg4/574 (0.7%)97/574 (16.9%)213/574 (37.1%)
Placebo8/563 (1.4%)108/563 (19.2%)203/563 (36.1%)
Most frequent serious events
Showing 10 of 168
Most frequent serious events
EventBrensocatib 10 mgBrensocatib 25 mgPlacebo
BronchiectasisRespiratory, thoracic and mediastinal disorders47/58248/57467/563
PneumoniaInfections and infestations11/58213/57416/563
COVID-19Infections and infestations4/5829/5746/563
HaemoptysisRespiratory, thoracic and mediastinal disorders3/5821/5746/563
Atrial fibrillationCardiac disorders2/5821/5744/563
CataractEye disorders1/5820/5743/563
Pancreatitis acuteGastrointestinal disorders0/5821/5742/563
Pneumonia aspirationInfections and infestations0/5820/5742/563
Pseudomonas infectionInfections and infestations2/5822/5742/563
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/5821/5742/563
Most frequent other events
Most frequent other events
EventBrensocatib 10 mgBrensocatib 25 mgPlacebo
COVID-19Infections and infestations89/582113/57483/563
HeadacheNervous system disorders39/58249/57439/563
NasopharyngitisInfections and infestations45/58236/57443/563
CoughRespiratory, thoracic and mediastinal disorders41/58235/57436/563
Back painMusculoskeletal and connective tissue disorders13/58217/57435/563
Urinary tract infectionInfections and infestations27/58230/57433/563

Baseline characteristics

The Intent-to-treat (ITT) analysis set included all participants who were randomized.

Age, Continuous
Age, Continuous(Years)Brensocatib 10 mgBrensocatib 25 mgPlaceboTotal
Mean59.8 ± 15.9260.6 ± 15.7860.0 ± 15.4460.2 ± 15.72
Sex: Female, Male
Sex: Female, Male(Participants)Brensocatib 10 mgBrensocatib 25 mgPlaceboTotal
Female3853603621107
Male198215201614
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Brensocatib 10 mgBrensocatib 25 mgPlaceboTotal
Hispanic or Latino177164170511
Not Hispanic or Latino3913973731161
Unknown or Not Reported15142049
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Brensocatib 10 mgBrensocatib 25 mgPlaceboTotal
Race — American Indian or Alaska Native86923
Race — Asian636464191
Race — Black or African American25310
Race — Native Hawaiian or Other Pacific Islander1012
Race — White4314304051266
Race — Other15131139
Race — Unknown or Not Reported484659153
Race — More than one race15111137
08

Study locations

373 sites
  • USA013
    Birmingham, Alabama 35233, United States
  • USA080
    Conway, Arkansas 72032, United States
  • USA044
    Little Rock, Arkansas 72205, United States
  • USA104
    Fresno, California 93702, United States
  • USA055
    Los Angeles, California 90048, United States
  • USA029
    Newport Beach, California 92663, United States
  • USA102
    Northridge, California 91324, United States
  • USA022
    Palm Springs, California 92262, United States
  • USA024
    Sacramento, California 95817, United States
  • USA035
    San Diego, California 92120, United States
  • USA078
    Santa Barbara, California 93105, United States
  • USA027
    Ventura, California 93003, United States
  • USA075
    Denver, Colorado 80206, United States
  • USA017
    Farmington, Connecticut 06030, United States
  • USA001
    Washington D.C., District of Columbia 20007, United States
  • USA015
    Clearwater, Florida 33765, United States
  • USA076
    Gainesville, Florida 32610, United States
  • USA082
    Jacksonville, Florida 32224, United States
  • USA039
    Kissimmee, Florida 34746, United States
  • USA072
    Leesburg, Florida 34748, United States
  • USA037
    Miami, Florida 33126, United States
  • USA019
    Miami Lakes, Florida 33014, United States
  • USA049
    Naples, Florida 34102, United States
  • USA052
    Orlando, Florida 32825, United States
  • USA103
    Plantation, Florida 33324, United States
  • USA084
    Sarasota, Florida 34239, United States
  • USA089
    St. Petersburg, Florida 33704, United States
  • USA074
    St. Petersburg, Florida 33707, United States
  • USA120
    Tampa, Florida 33606, United States
  • USA012
    Atlanta, Georgia 30342, United States
  • USA053
    Augusta, Georgia 30912, United States
  • USA073
    Chicago, Illinois 60611, United States
  • USA061
    Maywood, Illinois 60153, United States
  • USA115
    Hammond, Indiana 46324, United States
  • USA063
    Iowa City, Iowa 52242, United States
  • USA031
    Kansas City, Kansas 66160, United States
  • USA020
    New Orleans, Louisiana 70112, United States
  • USA051
    New Orleans, Louisiana 70112, United States
  • USA003
    Baltimore, Maryland 21224, United States
  • USA079
    Boston, Massachusetts 02114, United States
  • USA064
    Springfield, Massachusetts 01199, United States
  • USA010
    Rochester, Minnesota 55905, United States
  • USA006
    Chesterfield, Missouri 63017, United States
  • USA059
    St Louis, Missouri 63110, United States
  • USA110
    Lincoln, Nebraska 68510, United States
  • USA065
    Toms River, New Jersey 08755, United States
  • USA066
    New Hyde Park, New York 11042, United States
  • USA021
    New York, New York 10017, United States
  • USA085
    New York, New York 10032, United States
  • USA033
    Gastonia, North Carolina 28054, United States
  • USA096
    Huntersville, North Carolina 28078, United States
  • USA026
    Winston-Salem, North Carolina 27103, United States
  • USA067
    Cincinnati, Ohio 45267, United States
  • USA093
    Cleveland, Ohio 44195, United States
  • USA023
    Portland, Oregon 97239, United States
  • USA038
    DuBois, Pennsylvania 15801, United States
  • USA046
    Philadelphia, Pennsylvania 19104, United States
  • USA005
    Charleston, South Carolina 29425, United States
  • USA036
    Rock Hill, South Carolina 29732, United States
  • USA041
    Franklin, Tennessee 37067, United States
  • USA109
    Nashville, Tennessee 37232, United States
  • USA097
    Dallas, Texas 75246, United States
  • USA050
    McKinney, Texas 75069, United States
  • USA011
    San Antonio, Texas 78258, United States
  • USA002
    Tyler, Texas 75708, United States
  • USA034
    Williamsburg, Virginia 23188, United States
  • USA088
    Vancouver, Washington 98664, United States
  • ARG027
    Bahía Blanca, Buenos Aires 8000, Argentina
  • ARG021
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1121ABE, Argentina
  • ARG022
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1122AAK, Argentina
  • ARG002
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1414AIF, Argentina
  • ARG001
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1425AZB, Argentina
  • ARG003
    Ciudad Autónoma de BuenosAires, Buenos Aires C1425BEN, Argentina
  • ARG004
    Ciudad Autónoma de BuenosAires, Buenos Aires C1426ABP, Argentina
  • ARG006
    La Plata, Buenos Aires B1902COS, Argentina
  • ARG013
    Mar del Plata, Buenos Aires B7600FYK, Argentina
  • ARG017
    Mar del Plata, Buenos Aires CP 7600, Argentina
  • ARG009
    Villa Vatteone, Buenos Aires B1853AIK, Argentina
  • ARG012
    Buenos Aires, Ciudad Autónoma de BuenosAires C10227AAP, Argentina
  • ARG018
    Buenos Aires, Ciudad Autónoma de BuenosAires C1060, Argentina
  • ARG026
    Recoleta, Ciudad Autónoma de BuenosAires C1425EFD, Argentina
  • ARG023
    Río Cuarto, Córdoba Province 5800, Argentina
  • ARG014
    Vistalba, Mendoza Province M5544, Argentina
  • ARG010
    Rosario, Santa Fe Province S2000DTC, Argentina
  • ARG015
    San Miguel de Tucumán, Tucumán Province T4000IFL, Argentina
  • ARG025
    San Miguel de Tucumán, Tucumán Province T4000IHE, Argentina
  • ARG005
    Córdoba, X5003DCE, Argentina
  • ARG007
    Mendoza, M5500CCG, Argentina
  • ARG011
    Rosario, S2000JKR, Argentina
  • ARG019
    Santa Fe, 3000, Argentina
  • AUS013
    Kogarah, New South Wales 2217, Australia
  • AUS008
    New Lambton Heights, New South Wales 2305, Australia
  • AUS007
    Westmead, New South Wales 2145, Australia
  • AUS012
    Cairns North, Queensland 4870, Australia
  • AUS001
    Chermside, Queensland 4032, Australia
  • AUS010
    Greenslopes, Queensland 4120, Australia
  • AUS006
    South Brisbane, Queensland 4101, Australia
  • AUS019
    South Brisbane, Queensland 4101, Australia
  • AUS011
    Adelaide, South Australia 5000, Australia
  • AUS017
    Bedford Park, South Australia 5042, Australia

Showing the first 100 of 373 sites across 36 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Addrizzo-Harris D, Chalmers JD, Aliberti S, Burgel PR, Morrissey BM, Zhang X, Fan C, Lauterio M, Fucile S, Griffis D, Teper A. Efficacy and Safety of Brensocatib in Participants of Asian Race with Non-cystic Fibrosis Bronchiectasis: A Subgroup Analysis of the ASPEN Trial. Pulm Ther. 2026 Jul 16. doi: 10.1007/s41030-026-00375-w. Online ahead of print. PubMed 42461571 ↗
  • Morimoto K, Chalmers JD, Burgel PR, Daley CL, De Soyza A, Mauger D, Metersky ML, Zhang X, Li S, Goto Y, Teper A, Fernandez C, Hasegawa N. Efficacy and safety of brensocatib in Japanese patients with non-cystic fibrosis bronchiectasis: Analysis of the ASPEN trial. Respir Investig. 2026 Mar;64(2):101357. doi: 10.1016/j.resinv.2025.101357. Epub 2026 Jan 9. PubMed 41519018 ↗
  • Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML; ASPEN Investigators. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2025 Apr 24;392(16):1569-1581. doi: 10.1056/NEJMoa2411664. PubMed 40267423 ↗
  • Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Mange K, Teper A, Fernandez C, Conroy D, Metersky M. Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics. ERJ Open Res. 2024 Jul 22;10(4):00151-2024. doi: 10.1183/23120541.00151-2024. eCollection 2024 Jul. PubMed 39040578 ↗
  • Chalmers JD, Usansky H, Rubino CM, Teper A, Fernandez C, Zou J, Mange KC. Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis. Clin Pharmacokinet. 2022 Oct;61(10):1457-1469. doi: 10.1007/s40262-022-01147-w. Epub 2022 Jul 25. PubMed 35976570 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Oct 2024, 46 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2020
First posted
Oct 20, 2020
StartActual
Dec 1, 2020
Primary completionActual
Oct 28, 2024
CompletionActual
Oct 28, 2024
Results first posted
Dec 16, 2025
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04594369
Responsible party
Sponsor
First posted
Oct 20, 2020
Start date
Dec 1, 2020
Primary completion
Oct 28, 2024
Completion
Oct 28, 2024
Results posted
Dec 16, 2025
Last update
Dec 16, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brensocatib

Start the discussion